Pharmacological Considerations during Percutaneous Treatment of Heart Failure.

Autores de IIS La Fe

• José Luis Díez Gil

  Autor

• 

  Luis Vicente Martínez Dolz

  Autor

• Jorge Sanz Sánchez

  Autor

Participantes ajenos a IIS La Fe

• Sorolla-Romero JA
• Navarrete-Navarro J
• Martinez-Sole J
• Garcia HMG

Grupos

• Grupo de Investigación Clínica y Traslacional en Cardiología

Abstract

Heart Failure (HF) remains a global health challenge, marked by its widespread prevalence and substantial resource utilization. Although the prognosis has improved in recent decades due to the treatments implemented, it continues to generate high morbidity and mortality in the medium to long term. Interventional cardiology has emerged as a crucial player in HF management, offering a diverse array of percutaneous treatments for both acute and chronic HF. This article aimed to provide a comprehensive review of the role of percutaneous interventions in HF patients, with a primary focus on key features, clinical effectiveness, and safety outcomes. Despite the growing utilization of these interventions, there remain critical gaps in the existing body of evidence. Consequently, the need for high-quality randomized clinical trials and extensive international registries is emphasized to shed light on the specific patient populations and clinical scenarios that stand to benefit most from these innovative devices.

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Keywords

• ECMO, Heart failure, Impella, MitraClip, TandemHeart, TriClip., cardiogenic shock, interventional cardiology